GENENTECH'S COVID-19 RESPONSE
Genentech takes the health and safety of our patients, customers, employees and local communities very seriously. See below for information on how we're actively responding to the global COVID-19 pandemic.
News & Editorials
Phase III Combination Trial
Read about our Phase III trial testing the combination of two investigational medicines for severe COVID-19 pneumonia.
Learn More
A Call For More Inclusive COVID-19 Research
Let’s work together to place diversity and inclusion at the forefront of COVID-19 research.
Learn More
What Will We Learn From COVID-19?
A perspective on the actions we must take in response to and beyond the pandemic.
Learn More
Phase III Trial
Learn more about our Phase III trial for hospitalized patients with severe COVID-19 pneumonia.
Learn More
SARS-CoV-2 Test
Read the press release on the SARS-CoV-2 test from our parent company, Roche.
Learn More
Antibody Test
Read the press release on the new Anti-SARS-CoV-2 antibody test from our parent company, Roche.
Learn More
Community Support
Learn more about our commitment to help address the impacts of COVID-19 in our communities and across the U.S.
Learn More
Lessons in Giving During a Global Pandemic
Our approach to giving during the COVID-19 crisis has been guided by three principles: Embrace equity. Engage employees. Think long-term.
Learn More
If we all continue to work together, I believe science will ultimately prevail over this disease.
Information & Resources
Frequently Asked Questions
Read our responses to frequently asked questions regarding COVID-19 and Genentech.
Learn moreContact Information & Support Resources
View contact information and support resources for patients, medical professionals, and customers.
Learn morePatient Financial Support
We believe every person should get the Genentech medicine they need, and we offer programs to help make this happen.
Learn More